Ovid Therapeutics Inc [NASDAQ: OVID] gained 2.39% or 0.01 points to close at $0.34 with a heavy trading volume of 276889 shares.
It opened the trading session at $0.335, the shares rose to $0.3411 and dropped to $0.326, the range by which the price of stock traded the whole day. The daily chart for OVID points out that the company has recorded -64.64% loss over the past six months.
If we look at the average trading volume of 848.31K shares, OVID reached to a volume of 276889 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Ovid Therapeutics Inc [OVID]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OVID shares is $2.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OVID stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Ovid Therapeutics Inc shares, keeping their opinion on the stock as Perform, with their previous recommendation back on June 18, 2024. While these analysts kept the previous recommendation, B. Riley Securities raised their target price to Buy. The new note on the price target was released on April 30, 2024, representing the official price target for Ovid Therapeutics Inc stock. Previously, the target price had yet another raise to $9, while H.C. Wainwright analysts kept a Buy rating on OVID stock.
The Price to Book ratio for the last quarter was 0.41, with the Price to Cash per share for the same quarter was set at 0.60.
Trading performance analysis for OVID stock
Ovid Therapeutics Inc [OVID] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.34. With this latest performance, OVID shares gained by 13.29% in over the last four-week period, additionally sinking by -64.64% over the last 6 months – not to mention a drop of -63.76% in the past year of trading.
Ovid Therapeutics Inc [OVID]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Ovid Therapeutics Inc [OVID] shares currently have an operating margin of -10404.20% and a Gross Margin at -10.22%. Ovid Therapeutics Inc’s Net Margin is presently recorded at -4557.12%.
Return on Equity for this stock declined to -23.42%, with Return on Assets sitting at -23.42%.
An analysis of Institutional ownership at Ovid Therapeutics Inc [OVID]
There are presently around $55.97%, or 66.89% of OVID stock, in the hands of institutional investors. The top three institutional holders of OVID stocks are: TAKEDA PHARMACEUTICAL CO LTD with ownership of 7.53 million shares, which is approximately 10.6209%. RUBRIC CAPITAL MANAGEMENT LP, holding 5.32 million shares of the stock with an approximate value of $$4.09 million in OVID stocks shares; and RUBRIC CAPITAL MANAGEMENT LP, currently with $$3.14 million in OVID stock with ownership which is approximately 5.7562%.
